{
  "DOI": "10.1007/s10689-020-00160-x",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-020-00160-x",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eStudies have shown that a significant number of eligible breast cancer patients are not offered genetic testing or referral to genetic counseling. To increase access to genetic testing in South Eastern Norway, testing has since 2014 been offered directly to breast cancer patients by surgeons and oncologists. This practice is termed “mainstreamed genetic testing”. The aim of this study was to investigate to what extent patients in South Eastern Norway are offered testing. Three hundred and sixty one patients diagnosed in 2016 and 2017 at one regional and one university hospital in South Eastern Norway were included. Data on whether the patients fulfilled the criteria, whether they had been offered testing and if they were tested were collected. In total, 26.6% (96/361) fulfilled the criteria for testing. Seventy five percent (69/92) of these were offered testing, and 71.7% (66/92) were tested. At the university hospital, 90.2% (37/41) of eligible patients were offered testing, and at the regional hospital 62.7% (32/51). Fifty two percent (12/23) of eligible patient not offered testing were younger than 50 years at time of diagnosis. As many as 95.4% (125/131) of all patients who were offered testing, wanted to be tested. The majority of patients who fulfilled the criteria were offered testing, supporting the practice of mainstreamed genetic testing. There were nevertheless differences in rates of testing between the hospitals that affected all groups of patients, indicating that genetic testing may not be equally accessible to all patients. We suggest that efforts should be made to increase awareness and improve routines for genetic testing of breast cancer patients in Norway.\u003c/jats:p\u003e",
  "alternative-id": [
    "160"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 1,
      "value": "30 January 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflicts of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "Eli Marie Grindedal has received a grant from The Norwegian Cancer Society (Grant Number 194790–2017)."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The research project was evaluated by the Regional Committees for Medical and Health Research Ethics in South Eastern Norway. They defined it as a quality of care study, and thereby outside of their mandate. The study has been approved by the data protection officers at Oslo University Hospital (OUH), Ahus and IH."
    },
    {
      "group": {
        "label": "Informed consent",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 4,
      "value": "Informed consent was obtained from all individual participants included in the study."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-8198-1706",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Grindedal",
      "given": "Eli Marie",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Jørgensen",
      "given": "Kjersti",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Olsson",
      "given": "Pernilla",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Gravdehaug",
      "given": "Berit",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Lurås",
      "given": "Hilde",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Schlichting",
      "given": "Ellen",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Vamre",
      "given": "Tone",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Wangensteen",
      "given": "Teresia",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Heramb",
      "given": "Cecilie",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Mæhle",
      "given": "Lovise",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        1,
        30
      ]
    ],
    "date-time": "2020-01-30T06:04:05Z",
    "timestamp": 1580364245000
  },
  "deposited": {
    "date-parts": [
      [
        2021,
        1,
        29
      ]
    ],
    "date-time": "2021-01-29T00:41:35Z",
    "timestamp": 1611880895000
  },
  "funder": [
    {
      "DOI": "10.13039/100008730",
      "award": [
        "194790-2017"
      ],
      "doi-asserted-by": "publisher",
      "name": "Kreftforeningen"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        1
      ]
    ],
    "date-time": "2024-03-01T03:46:15Z",
    "timestamp": 1709264775226
  },
  "is-referenced-by-count": 14,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "2",
  "issued": {
    "date-parts": [
      [
        2020,
        1,
        30
      ]
    ]
  },
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2020,
          4
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            1,
            30
          ]
        ],
        "date-time": "2020-01-30T00:00:00Z",
        "timestamp": 1580342400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            1,
            30
          ]
        ],
        "date-time": "2020-01-30T00:00:00Z",
        "timestamp": 1580342400000
      }
    }
  ],
  "link": [
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s10689-020-00160-x.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/article/10.1007/s10689-020-00160-x/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s10689-020-00160-x.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "133-142",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2020,
        1,
        30
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        1,
        30
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2020,
        4
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "author": "A Antoniou",
      "first-page": "1117",
      "journal-title": "Am J Med Genet",
      "key": "160_CR1",
      "unstructured": "Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Med Genet 72:1117–1130",
      "volume": "72",
      "year": "2003"
    },
    {
      "DOI": "10.1126/science.1088759",
      "author": "MC King",
      "doi-asserted-by": "publisher",
      "first-page": "643",
      "journal-title": "Science",
      "key": "160_CR2",
      "unstructured": "King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646",
      "volume": "302",
      "year": "2003"
    },
    {
      "DOI": "10.1001/jama.2017.7112",
      "author": "KB Kuchenbaecker",
      "doi-asserted-by": "publisher",
      "first-page": "2402",
      "issue": "23",
      "journal-title": "JAMA",
      "key": "160_CR3",
      "unstructured": "Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112",
      "volume": "317",
      "year": "2017"
    },
    {
      "DOI": "10.1136/bmj.g226",
      "author": "K Metcalfe",
      "doi-asserted-by": "publisher",
      "first-page": "g226",
      "journal-title": "BMJ",
      "key": "160_CR4",
      "unstructured": "Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226. https://doi.org/10.1136/bmj.g226",
      "volume": "348",
      "year": "2014"
    },
    {
      "DOI": "10.1056/NEJMoa0900212",
      "author": "PC Fong",
      "doi-asserted-by": "publisher",
      "first-page": "123",
      "issue": "2",
      "journal-title": "N Engl J Med",
      "key": "160_CR5",
      "unstructured": "Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123–134. https://doi.org/10.1056/NEJMoa0900212",
      "volume": "361",
      "year": "2009"
    },
    {
      "DOI": "10.1016/S0140-6736(10)60892-6",
      "author": "A Tutt",
      "doi-asserted-by": "publisher",
      "first-page": "235",
      "issue": "9737",
      "journal-title": "Lancet",
      "key": "160_CR6",
      "unstructured": "Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244. https://doi.org/10.1016/S0140-6736(10)60892-6",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.breast.2015.07.032",
      "author": "DG Stover",
      "doi-asserted-by": "publisher",
      "first-page": "S132",
      "journal-title": "Breast",
      "key": "160_CR7",
      "unstructured": "Stover DG, Winer EP (2015) Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast 24:S132–S135. https://doi.org/10.1016/j.breast.2015.07.032",
      "volume": "24",
      "year": "2015"
    },
    {
      "DOI": "10.1016/S1470-2045(13)70240-7",
      "author": "SK Sandhu",
      "doi-asserted-by": "publisher",
      "first-page": "882",
      "issue": "9",
      "journal-title": "Lancet Oncol",
      "key": "160_CR8",
      "unstructured": "Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882–892. https://doi.org/10.1016/S1470-2045(13)70240-7",
      "volume": "14",
      "year": "2013"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-15-2137",
      "author": "ET Rodler",
      "doi-asserted-by": "publisher",
      "first-page": "2855",
      "issue": "12",
      "journal-title": "Clin Cancer Res",
      "key": "160_CR9",
      "unstructured": "Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Sheperd S, Giranda V, Specht JM (2016) Phase I study of Veliparib (ABT-888) combined with Cisplatin and Vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. Clin Cancer Res 22(12):2855–2864. https://doi.org/10.1158/1078-0432.CCR-15-2137",
      "volume": "22",
      "year": "2016"
    },
    {
      "DOI": "10.1200/JCO.2007",
      "author": "ND Kauff",
      "doi-asserted-by": "publisher",
      "first-page": "1331",
      "issue": "8",
      "journal-title": "J Clin Oncol",
      "key": "160_CR10",
      "unstructured": "Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatine P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331–1337. https://doi.org/10.1200/JCO.2007",
      "volume": "26",
      "year": "2008"
    },
    {
      "DOI": "10.1136/jmg.2008.062232",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "254",
      "issue": "4",
      "journal-title": "J Med Genet",
      "key": "160_CR11",
      "unstructured": "Evans DG, Baildam AD, Anderson E, Brain A, Shenton A, Vasen HF, Eccles D, Lucassen A, Pichert G, Hamed H, Moller P, Maehle L, Morrison PJ, Stoppat-Lyonnet D, Gregory H, Smyth E, Niederacher D, Nestle-Krämling C, Campbell J, Hopwood P, Lalloo F, Howell A (2009) Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet 46(4):254–258. https://doi.org/10.1136/jmg.2008.062232",
      "volume": "46",
      "year": "2009"
    },
    {
      "DOI": "10.1001/jama.2010.1237",
      "author": "SM Domchek",
      "doi-asserted-by": "publisher",
      "first-page": "967",
      "issue": "9",
      "journal-title": "JAMA",
      "key": "160_CR12",
      "unstructured": "Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR, (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975. https://doi.org/10.1001/jama.2010.1237",
      "volume": "304",
      "year": "2010"
    },
    {
      "key": "160_CR13",
      "unstructured": "Norwegian Breast Cancer Group: National guidelines for diagnostics, treatment and follow-up of patients with breast cancer: https://nbcg.no/retningslinjer/content/text_7aca3287-7ec2-4c46-85c3-1ea97fd42377/1455823579701/brystkreftbehandlingsprogram_10_02.pdf. Accessed 15 February 2019"
    },
    {
      "key": "160_CR14",
      "unstructured": "NCCN Guidelines Version 3.2019 Genetic/Familial High-Risk Assessment: Breast and Ovarian: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 15 February 2019"
    },
    {
      "key": "160_CR15",
      "unstructured": "National Institute for Health and Care Excellence: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer: NICE guidelines https://www.nice.org.uk/guidance/cg164. Accessed 15 February 2019"
    },
    {
      "DOI": "10.1016/j.ygyno.2015.04.029",
      "author": "T Febbraro",
      "doi-asserted-by": "publisher",
      "first-page": "109",
      "journal-title": "Gynecol oncol",
      "key": "160_CR16",
      "unstructured": "Febbraro T, Robison K, Wilbur JS, Laprise J, Bregar A, Lopes V, Legare R, Stuckley A (2015) Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol oncol 138:109–114. https://doi.org/10.1016/j.ygyno.2015.04.029",
      "volume": "138",
      "year": "2015"
    },
    {
      "DOI": "10.1200/JCO.2017.73.6314",
      "author": "CP Childers",
      "doi-asserted-by": "publisher",
      "first-page": "3800",
      "journal-title": "J Clin Oncol",
      "key": "160_CR17",
      "unstructured": "Childers CP, Childers KK, Maggard-Gibbons M, Macinko J (2017) National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol 35:3800–3806.https://doi.org/10.1200/JCO.2017.73.6314",
      "volume": "35",
      "year": "2017"
    },
    {
      "DOI": "10.1097/IGC.0b013e318280f2b4",
      "author": "CB Powell",
      "doi-asserted-by": "publisher",
      "first-page": "431",
      "issue": "3",
      "journal-title": "Int J Gynecol Cancer",
      "key": "160_CR18",
      "unstructured": "Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A (2013) Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer 23(3):431–436. https://doi.org/10.1097/IGC.0b013e318280f2b4",
      "volume": "23",
      "year": "2013"
    },
    {
      "DOI": "10.1007/s10689-016-9953-x",
      "author": "MP Nilsson",
      "doi-asserted-by": "publisher",
      "first-page": "187",
      "issue": "2",
      "journal-title": "Fam Cancer",
      "key": "160_CR19",
      "unstructured": "Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, Loman N (2017) Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Fam Cancer 16(2):187–193. https://doi.org/10.1007/s10689-016-9953-x",
      "volume": "16",
      "year": "2017"
    },
    {
      "DOI": "10.1080/0284186X.2017.1404635",
      "author": "A Augustinsson",
      "doi-asserted-by": "publisher",
      "first-page": "595",
      "issue": "5",
      "journal-title": "Acta Oncol",
      "key": "160_CR20",
      "unstructured": "Augustinsson A, Ellberg C, Kristoffersson U, Borg A, Olsson H (2018) Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer. Acta Oncol 57(5):595–603. https://doi.org/10.1080/0284186X.2017.1404635",
      "volume": "57",
      "year": "2018"
    },
    {
      "DOI": "10.1186/s12885-017-3422-",
      "author": "EM Grindedal",
      "doi-asserted-by": "publisher",
      "first-page": "438",
      "issue": "1",
      "journal-title": "BMC Cancer",
      "key": "160_CR21",
      "unstructured": "Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Maehle L, Undlien DE, Norum J, Schlichting E (2017) Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer 17(1):438. https://doi.org/10.1186/s12885-017-3422-",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-105140",
      "author": "B Rahman",
      "doi-asserted-by": "publisher",
      "first-page": "195",
      "issue": "3",
      "journal-title": "J Med Genet",
      "key": "160_CR22",
      "unstructured": "Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, Lockley M, McCormack M, Mould T, Side L (2019) Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet 56(3):195–198. https://doi.org/10.1136/jmedgenet-2017-105140",
      "volume": "56",
      "year": "2019"
    },
    {
      "DOI": "10.1200/JCO.2017.74.7899",
      "author": "KS Hughes",
      "doi-asserted-by": "publisher",
      "first-page": "3789",
      "issue": "34",
      "journal-title": "J Clin Oncol",
      "key": "160_CR23",
      "unstructured": "Hughes KS (2017) Genetic testing: what problem are we trying to solve? J Clin Oncol 35(34):3789–3791. https://doi.org/10.1200/JCO.2017.74.7899",
      "volume": "35",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s12687-013-0166-9",
      "author": "T Pal",
      "doi-asserted-by": "publisher",
      "first-page": "157",
      "issue": "2",
      "journal-title": "J Commun Genet",
      "key": "160_CR24",
      "unstructured": "Pal T, Bonner D, Cragun D, Johnson S, Akbari M, Servais L, Narod S, Vadaparampil S (2014) BRCA sequencing and large rearrangement testing in young black women with breast cancer. J Commun Genet 5(2):157–165. https://doi.org/10.1007/s12687-013-0166-9",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.1007/s10555-018-9761-x",
      "author": "RA Leon-Ferre",
      "doi-asserted-by": "publisher",
      "first-page": "599",
      "issue": "4",
      "journal-title": "Cancer Metastasis Rev.",
      "key": "160_CR25",
      "unstructured": "Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, Hawse JR, Boughey JC, Ruddy KJ (2018) A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev. 37(4):599–614. https://doi.org/10.1007/s10555-018-9761-x",
      "volume": "37",
      "year": "2018"
    },
    {
      "DOI": "10.1038/ejhg.2015.196",
      "author": "H Hoberg-Vetti",
      "doi-asserted-by": "publisher",
      "first-page": "881",
      "issue": "6",
      "journal-title": "Eur J Hum Genet",
      "key": "160_CR26",
      "unstructured": "Hoberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N (2016) BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet 24(6):881–888. https://doi.org/10.1038/ejhg.2015.196",
      "volume": "24",
      "year": "2016"
    },
    {
      "key": "160_CR27",
      "unstructured": "https://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html. Accessed 15 February 2019."
    },
    {
      "DOI": "10.1016/j.clinbiochem.2019.11.014",
      "author": "M Rodríguez-Balada",
      "doi-asserted-by": "publisher",
      "journal-title": "Clin Biochem",
      "key": "160_CR28",
      "unstructured": "Rodríguez-Balada M, Roig B, Melé M, Albacar C, Serrano S, Salvat M, Querol M, Borràs J, Martorell L, Gumà J (2019) Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Clin Biochem. https://doi.org/10.1016/j.clinbiochem.2019.11.014",
      "year": "2019"
    },
    {
      "DOI": "10.1002/cam4.1376",
      "author": "J Hauke",
      "doi-asserted-by": "publisher",
      "first-page": "1349",
      "issue": "4",
      "journal-title": "Cancer Med.",
      "key": "160_CR29",
      "unstructured": "Hauke J, Horvath J, Groß E, Gehrig A, Honisch E, Hackmann K, Schmidt G, Arnold N, Faust U, Sutter C, Hentschel J, Wang-Gohrke S, Smogavec M, Weber BHF, Weber-Lassalle N, Weber-Lassalle K, Borde J, Ernst C, Altmüller J, Volk AE, Thiele H, Hübbel V, Nürnberg P, Keupp K, Versmold B, Pohl E, Kubisch C, Grill S, Paul V, Herold N, Lichey N, Rhiem K, Ditsch N, Ruckert C, Wappenschmidt B, Auber B, Rump A, Niederacher D, Haaf T, Ramser J, Dworniczak B, Engel C, Meindl A, Schmutzler RK, Hahnen E (2018) Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med. 7(4):1349–1358. https://doi.org/10.1002/cam4.1376",
      "volume": "7",
      "year": "2018"
    },
    {
      "DOI": "10.1245/s10434-017-5963-7",
      "author": "E O'Leary",
      "doi-asserted-by": "publisher",
      "first-page": "3060",
      "issue": "10",
      "journal-title": "Ann Surg Oncol.",
      "key": "160_CR30",
      "unstructured": "O'Leary E, Iacoboni D, Holle J, Michalski ST, Esplin ED, Yang S, Ouyang K (2017) Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk. Ann Surg Oncol. 24(10):3060–3066. https://doi.org/10.1245/s10434-017-5963-7",
      "volume": "24",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s00432-018-2763-9",
      "author": "S Bonache",
      "doi-asserted-by": "publisher",
      "first-page": "2495",
      "issue": "12",
      "journal-title": "J Cancer Res Clin Oncol.",
      "key": "160_CR31",
      "unstructured": "Bonache S, Esteban I, Moles-Fernández A, Tenés A, Duran-Lozano L, Montalban G, Bach V, Carrasco E, Gadea N, López-Fernández A, Torres-Esquius S, Mancuso F, Caratú G, Vivancos A, Tuset N, Balmaña J, Gutiérrez-Enríquez S, Diez O (2018) Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. J Cancer Res Clin Oncol. 144(12):2495–2513. https://doi.org/10.1007/s00432-018-2763-9",
      "volume": "144",
      "year": "2018"
    },
    {
      "DOI": "10.1158/1055-9965.EPI-12-1280",
      "author": "CA Bellcross",
      "doi-asserted-by": "publisher",
      "first-page": "728",
      "issue": "4",
      "journal-title": "Cancer Epidemiol Biomark Prev.",
      "key": "160_CR32",
      "unstructured": "Bellcross CA, Leadbetter S, Alford SH, Peipins LA (2013) Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomark Prev. 22(4):728–735. https://doi.org/10.1158/1055-9965.EPI-12-1280",
      "volume": "22",
      "year": "2013"
    },
    {
      "DOI": "10.1038/gim.2014.68",
      "author": "CA Bellcross",
      "doi-asserted-by": "publisher",
      "first-page": "43",
      "issue": "1",
      "journal-title": "Genet Med.",
      "key": "160_CR33",
      "unstructured": "Bellcross CA, Peipins LA, McCarty FA, Rodriguez JL, Hawkins NA, Hensley Alford S, Leadbetter S (2015) Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. Genet Med. 17(1):43–50. https://doi.org/10.1038/gim.2014.68",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.1007/s12687-017-0326-4",
      "author": "JAM van der Giessen",
      "doi-asserted-by": "publisher",
      "first-page": "303",
      "issue": "4",
      "journal-title": "J Commun Genet",
      "key": "160_CR34",
      "unstructured": "van der Giessen JAM, van Riel E, Velthuizen ME, van Dulmen AM, Ausems MGEM (2017) Referral to cancer genetic counseling: do migrant status and patients' educational background matter? J Commun Genet 8(4):303–310. https://doi.org/10.1007/s12687-017-0326-4",
      "volume": "8",
      "year": "2017"
    },
    {
      "DOI": "10.1007/s40615-018-00556-7",
      "author": "CD Williams",
      "doi-asserted-by": "publisher",
      "first-page": "570",
      "issue": "3",
      "journal-title": "J Racial Ethn Health Disparities.",
      "key": "160_CR35",
      "unstructured": "Williams CD, Bullard AJ, O'Leary M, Thomas R, Redding TS 4th, Goldstein K (2019) Racial/ethnic disparities in BRCA counseling and testing: a narrative review. J Racial Ethn Health Disparities. 6(3):570–583. https://doi.org/10.1007/s40615-018-00556-7",
      "volume": "6",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s10689-016-9921-5",
      "author": "DS Chun",
      "doi-asserted-by": "publisher",
      "first-page": "41",
      "issue": "1",
      "journal-title": "Fam Cancer.",
      "key": "160_CR36",
      "unstructured": "Chun DS, Berse B, Venne VL, DuVall SL, Filipski KK, Kelley MJ, Meyer LJ, Icardi MS, Lynch JA (2017) BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. Fam Cancer. 16(1):41–49. https://doi.org/10.1007/s10689-016-9921-5",
      "volume": "16",
      "year": "2017"
    },
    {
      "DOI": "10.1038/gim.2017.118",
      "author": "Z Chen",
      "doi-asserted-by": "publisher",
      "first-page": "428",
      "issue": "4",
      "journal-title": "Genet Med.",
      "key": "160_CR37",
      "unstructured": "Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ (2018) Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med. 20(4):428–434. https://doi.org/10.1038/gim.2017.118",
      "volume": "20",
      "year": "2018"
    },
    {
      "DOI": "10.1080/08998280.2019.1612702",
      "author": "A Swink",
      "doi-asserted-by": "publisher",
      "first-page": "340",
      "issue": "3",
      "journal-title": "Bayl Univ Med Center Proc.",
      "key": "160_CR38",
      "unstructured": "Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL (2019) Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers. Bayl Univ Med Center Proc. 32(3):340–344. https://doi.org/10.1080/08998280.2019.1612702",
      "volume": "32",
      "year": "2019"
    },
    {
      "DOI": "10.1001/jama.2016.16918",
      "author": "AW Kurian",
      "doi-asserted-by": "publisher",
      "first-page": "531",
      "issue": "5",
      "journal-title": "JAMA",
      "key": "160_CR39",
      "unstructured": "Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, Jagsi R (2017) Genetic testing and counseling among patients With newly diagnosed breast cancer. JAMA 317(5):531–534. https://doi.org/10.1001/jama.2016.16918",
      "volume": "317",
      "year": "2017"
    },
    {
      "author": "Cancer Registry of Norway",
      "key": "160_CR40",
      "unstructured": "Cancer Registry of Norway (2018) Cancer Incidence in Norway 2017—Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, Oslo",
      "volume-title": "Cancer Incidence in Norway 2017—Cancer incidence, mortality, survival and prevalence in Norway",
      "year": "2018"
    }
  ],
  "reference-count": 40,
  "references-count": 40,
  "relation": {
    "has-preprint": [
      {
        "asserted-by": "object",
        "id": "10.21203/rs.2.15182/v1",
        "id-type": "doi"
      }
    ]
  },
  "resource": {
    "primary": {
      "URL": "http://link.springer.com/10.1007/s10689-020-00160-x"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "19"
}